European Union regulators are reviewing filings for two cancer drug candidates from Pfizer Inc., whose drug R&D operations are in Groton, The Associated Press reports.
New York-based Pfizer said Wednesday the European Medicines Agency accepted its market application for crizotinib as a treatment for lung cancer, and for bosutinib as a treatment for chronic myeloid leukemia. Pfizer did not say how long it expects the reviews to take.
The two drugs are important parts of Pfizer’s development pipeline. That’s particularly true of crizotinib, a twice-a-day pill that is intended for lung cancer patients whose tumors have a genetic rearrangement of an enzyme that stimulates growth and survival of those cancer cells. It is intended to treat advanced non-small cell lung cancer, which is diagnosed in about 50,000 people worldwide every year. Analysts believe the drug could bring Pfizer billions of dollars in annual revenue.
